News | May 13, 2007

Edwards Alleges Patent Infringement Over Transcatheter Heart Valve

May 15, 2007 — Edwards Lifesciences Corp. announced last week that its subsidiary, Edwards Lifesciences PVT, Inc., has filed a patent infringement lawsuit against CoreValve Inc., of Irvine, Calif., in the District Court of Dusseldorf, Germany. The suit seeks relief for alleged infringement of a patent for transcatheter heart valve technology.

"We are committed to protecting our valuable intellectual property as well as the interests of our clinician-inventors who partner with us to transform patient care for people with advanced cardiovascular disease," said Michael A. Mussallem, Edwards' chairman and CEO. The company has opened discussions with CoreValve on a possible licensing arrangement.

The patent in question, EP 0 592 410 B1, is co-owned by Dr. Henning Rud Andersen of Aarhus, Denmark, and his colleagues, who licensed it in 1993 to Heartport, Inc., now a subsidiary of Johnson & Johnson. Edwards has an exclusive sublicense to the Andersen patent for cardiovascular applications. The patent relates to a valve prosthesis for implantation by means of a catheter, and the product named in the suit is the CoreValve ReValving System.

For more information about Edwards visit www.edwards.com.

Related Content

Mick Jagger Recovering After TAVR Procedure
News | Heart Valve Technology | April 08, 2019 | Jeff Zagoudis, Associate Editor
Rolling Stones frontman Mick Jagger is reportedly recovering after undergoing a transcatheter aortic valve valve...
 Evolut Low Risk Trial compared the minimally invasive Evolut transcatheter aortic valve replacement (TAVR) system to the gold standard of open-heart surgery in characteristically younger, healthier aortic stenosis patients. The randomized trial, which met its primary non-inferiority endpoint of all-cause mortality or disabling stroke at two years compared to surgery (5.3 vs. 6.7 percent; posterior probability of non-inferiority >0.999), was presented at the American College of Cardiology (ACC) 2019 meeting
News | Heart Valve Technology | April 03, 2019
April 3, 2019 – The ACC.19 late-breaking landmark Evolut Low Risk Trial compared the minimally invasive Evolut transc
TAVR Outperforms Surgery in Younger, Low-Risk Aortic Stenosis Patients
News | Heart Valve Technology | March 22, 2019
Among patients with severe symptomatic aortic stenosis at low surgical risk, transcatheter aortic valve replacement (...
ACC Launches Transcatheter Valve Certification
News | Heart Valve Technology | March 14, 2019
March 14, 2019 — Beginning in mid-2019, hospitals performing...
FDA Approves MitraClip for Use in Heart Failure Patients With Functional Mitral Regurgitation
Feature | Heart Valve Technology | March 14, 2019 | Jeff Zagoudis, Associate Editor
March 14, 2019 — The U.S.
Scientists Discover New Type of Immune Cells Essential for Forming Heart Valves

Microscopic images of a normal heart valve in a mouse, left, and a heart valve grown in a lab with heart-derived macrophages blocked, right. Without those macrophages, the valves are thick and deformed. Image courtesy of Developmental Cell/UCLA Broad Stem Cell Research Center.

News | Heart Valve Technology | March 06, 2019
UCLA researchers have identified for the first time the origin of an immune cell that plays a critical role in the...
Global Market for Transcatheter Treatments to Double in Next Five Years
News | Heart Valve Technology | March 01, 2019
When it comes to treatment options for a damaged heart valve, nothing is getting more attention than transcatheter...
Overlay Init